Amgen: Low LDL Levels With Repatha Did Not Affect Cognitive Function In Study – Nasdaq
New York Times |
Amgen: Low LDL Levels With Repatha Did Not Affect Cognitive Function In Study
Nasdaq (RTTNews.com) – Amgen Inc. ( AMGN ) announced results from the Repatha or evolocumab cognitive function trial (EBBINGHAUS) evaluating the impact on cognitive function in 1,974 patients enrolled in the Repatha cardiovascular outcomes study, … Cholesterol-Slashing Drug Can Protect High-Risk Heart Patients, Study Finds Cholesterol drug cuts heart risks, spurs new debate on cost A pricey drug cuts cardiovascular risks in clinical trial — but will insurers cover it? |
Powered by WPeMatico